Combining Homologous Recombination-Deficient Testing and Functional RAD51 Analysis Enhances the Prediction of Poly(ADP-Ribose) Polymerase Inhibitor Sensitivity.

"ascn analysis was performed via the eacon r package version 0 3 6 available on github.; the ldt hrd score was computed using the ovahrdscar package available on github."

"Maria Rossing: Consulting or Advisory Role: AstraZeneca, MSD: Research Funding: AstraZeneca (Inst): No other potential conflicts of interest were reported."

"Research Funding: GlaxoSmithKline Research Funding: AstraZeneca (Inst), Boehringer Ingelheim (Inst), Pfizer (Inst), Tesaro (Inst), Clovis Oncology (Inst), Ultimovacs (Inst), Apexigen (Inst), GlaxoSmithKline (Inst) Research Funding: AstraZeneca (Inst)"

"The AVANOVA trial protocol and all amendments were approved by the research ethics committee/institutional review boards (IRBs) and the competent authorities of the participating hospitals and countries (ClinicalTrials.gov identifier: NCT02354131). The trial was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All patients provided written informed consent and consented to upfront HRD testing by Myriad. The reuse of the same archival tumor tissue samples for genomic subanalysis, including the results presented in this paper, has been approved by the research ethics committee/IRBs of the participating hospitals and countries. Approval was given to analyze tissue from patients already deceased or terminally ill without renewal of consent. Patients still alive were asked for written consent."